Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.
Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.
